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Summary.-Potential anti-cancer agents have classically undergone clinical assess-
ment in Phase I, II and III trials. This paper examines the role ofthese trials and pre-
clinical studies in the light of improving cancer chemotherapy. Many patients must
now be treated with standard therapy before investigational drugs can be ethically
used. The introduction of combined modality trials will require a very prolonged
follow-up to demonstrate improved survival and recognize late onset of chronic
toxicity.
CANCER chemotherapy has made many
advances in the treatment of malignant
diseases. It is paradoxical that the often
dramatic improvements in the treatment
of these patients have now led to our
present difficulties in the development of
new agents.
In the 25 years since the National
Cancer Institute modified the FDA-
derived Phase I, II and III trials it has
often become difficult to test new drugs,
as they may only ethically be given to
patients who have failed standard therapy.
At the time that these methods came
into use, drug trials were simple clinical
experiments in which some evidence of
activity as a single agent was the end
point. Most drugs tested showed low or
moderate levels of activity, producing
only minimal clinical responses. However,
drugs are now combined so that they are
more effective and are capable of produc-
ing frequent good responses and complete
remissions in a number of tumours.
These improvements in chemotherapy
have frequently made it difficult to test
new drugs adequately. Many of the
patients who can ethically be used in
Phase I and II clinical trials are of low
performance status, having received pre-
vious chemotherapy and/or radiotherapy,
and are the patients who could be least
expected to respond to further treatment.
Thus, as we improve chemotherapy, it will
become more difficult to test new drugs or
analogues of existing ones, as many
patients must be given standard treat-
ment before we can ethically embark on
treatments of unknown efficacy.
The situation is further complicated by
the introduction of combined-modality
therapy which includes chemotherapy.
Though the methodology of such trials is
still being worked out, it is already clear
that these trials will be a major under-
taking, requiring prolonged follow-up of
patients for 10-20 years, if we are to learn
the true impact of treatment on survival
and the incidence of chronic or late-onset
complications.
Preclinical studies
Preclinical studies are performed in
various animals and in vitro systems to
assess the potential activity and toxicity
of new drugs. While these studies are
important in the selection of potentially
active agents it is the results of Phase I
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and II trials that determine whether a new
drug will be fully assessed for clinical use.
Experimental models
The use of experimental models in the
selection of "active" compounds intro-
duces many problems, the major of those
being the selection of model test systems
which are able to identify compounds
with a high likelihood of clinical activity,
(Carter, 1973). Although all systems are
capable ofproducing true or false positives
and negatives, it is not possible to know
the false negative rate in present experi-
mental models, as drugs which are negative
never come to clinical trial.
All screening programmes must involve
compromise, and it is clear that some
compounds which would be clinically
active are not detected by the present
model systems and never reach clinical
trial.
Owing to the logistic problem of testing
large numbers of compounds of unknown
efficacy in potential new model systems, it
has been the policy ofmost centres working
in this field only to use drugs of known
efficacy in the detection of new model
systems. Unfortunately, these particular
drugs will have been identified by present
systems which will have missed potentially
active drugs. Thus, new systems will tend
to mimic systems already in use, and may
also fail to identify those "active" drugs
missed by present systems.
Fortunately, compounds of known act-
ivity were not predicted by one system,
and this provides a heterogeneity that can
be used in evaluating new model systems.
For example, Fig. 1 illustrates an approach
which tests a new system against a num-
ber of drugs found to be active in L1210
and an equal number of drugs inactive in
L1210, but active in other predictive
models. The new system would be highly
desirable if it showed activity by all the
L1210-inactive drugs (even if it indicated
lackofactivity forthe L1210-active drugs).
The opposite result would be unattractive
as it would only mimic the L1210 system.
Most systems fall between these two
LI210 Active
Cyclophosphamide
Adriamycin
Methotrexate
5-Fluorouracil
Nitrosoureas
Phenylalanine mustard
Cytosine arabinoside
6-Mercaptopurine
Imidazole carboxamide
Hydrozyurea
LI210 Inactive
Vincristine
Bleomycin
Hexamethylmelamine
Dactinomycin
Vinblastine
Streptozotocin
Prednisone
Dibromomannitol
Mithramycin
Myleran
10 L1210 +
New system
\ /~~~+
10 L1210 -
FIG. 1. Drug activity in L1210 as an
approach to evaluating a new screeninig
system.
extremes, but such an evaluation is helpful
in testing a new experimental system.
Another approach is to repeat a similar
trial (Fig. 2) but to divide the drugs
between those most active in haemato-
logic malignancies and those most active
in solid tumours. (It is of note that only
2 drugs, methotrexate and cyclophos-
phamide, appear in both lists.)
Top 10 leukaemia drugs
Vincristine
Prednisone
Methotrexate
6-Mercaptopurine
Cytosine arabinoside
Daunorubicin
L-Asparaginase
6-Thioguanine
Cyclophosphamide
Hydrozyurea
Top IO solid-tumour drugs
Cyclophosphamide
Adriamycin
Methotrexate
5-Fluorouracil
Nitrosoureas
Pnenylalanlne mustard
Hexamethylmelamine
Mitomycin C
Bleomycin
Dactinomycin
10 leukaemia drugs
New system
X /~~~~~+ 10 solid-tumour drugs
FIG. 2. Drug activity in leukaemia and
solid tumours as an approach to evaluating
a new screening system.
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Combinations of these approaches may
be useful in uncovering new experimental
systems applicable to certain tumour
types. These techniques have been used by
the NCI in the development of the B16
melanoma, P-388 leukaemia and Lewis
Lung carcinoma systems. Use of these
techniques will, we hope, allow the
development of models capable of identi-
fying some active drugs which have been
missed in the past, as mass screening of
new drugs in new model systems would be
too costly and slow to justify it as an
alternative method.
Toxicity
The extrapolation of data from animal
to man poses many difficulties, though we
have learned to predict toxicity in man
with reasonable accuracy. Studies (Owens,
1962; Schein, Davies and Cooney, 1973)
retrospectively comparing toxicities in
animal species and man have shown that
human toxicities in the haematopoietic,
gastro-intestinal, renalandhepaticsystems
can generally be predicted from data
collected in animals. However, in the
two most commonly used large animal
species (dog and monkey) there is a
tendency to over-predict toxicity, espec-
ially in the renal and hepatic systems. In
many animals, organ system toxicities are
obtained at severely toxic and lethal doses.
This may account for some of the over-
prediction, since drugs are not given at
such high levels in man.
Skin, cardiac and peripheral-nervous-
system toxicity are not well predicted, and
the detection of central-nervous-system
toxicity is dependent on the care with
which animals are assessed neurologically.
Specific parameters of toxicity, such as
leucopenia in the haematopoietic system,
are less accurately predicted than broad
organ toxicities. Thus, anaemia may be
the predominant haematopoietic toxicity
in animals, whilst leucopenia may pre-
dominate in man.
A number of studies (Freireich et al.,
1976, Homan, 1972; Pinkel, 1958) have
shown that a better correlation exists
between toxic doses among animal species
and man when the dose is expressed in
terms ofbody surface area (mg/M2) rather
than body weight (mg/kg). Toxicity
according to the blood or plasma level
achieved has not been correlated, and
might prove to be a more accurate pre-
dictor of toxicity and activity.
Various investigators have tried to
define a safe starting dose in man by
correlating the toxic doses in animal
species and man. Freireich et al. (1976)
suggested that one-third of the maxi-
mum tolerated dose defined by the
weighted estimate of 5 animal species
(in mg/M2) would be a safe starting dose for
most chemotherapy trials. However,
Homan (1972) estimated that complete
reliance on the use of one-third of the
MTD ("dose which produced only minimal
reversible toxicity") of the most sensitive
large animal species (usually dog or
monkey) gives a 6% probability of a toxic
starting dose in man.
In the most recent analysis of this type
(Goldsmith, Slavik and Carter, 1975) one
third ofthe "toxic dose low" (TDL mg/M2)
for the dog and one third of the LD10
(mg/M2) in mice was compared with the
"commonly used clinical dose" in man.
The TDL is defined as the "lowest dose to
produce pathologic alterations in haema-
tologic, chemical, clinical or morphologic
parameters; doubling this dose produces
no lethality". The mouse LD10 is the dose
that kills 10% of the animals. Although
the "commonly used clinical dose" in man
may not represent the MTD, it is the dose
that generally produces toxicity and may
yield therapeutic effects. This analysis
by Goldsmith et al. (1975) was performed
to see how often the "commonly used
human dose" would have been exceeded if
the starting dose had been based on the
animal data. Identical dose schedules were
frequently not used in animals and man,
and cumulative doses from animal sched-
ules were correlated to those used in man
by a method described by Freireich et al.
(1976). However, this conversion relies on
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toxicity being related to the cumulative
dose, regardless of schedule and this
assumption has not been validated. Using
this method, Goldsmith et al. (1975)
showed that reliance on the 1/3 TDL, as
used in most NCI trials, would have
resulted in a dose exceeding the "common-
ly used human dose" in 5/30 (17%) of the
trials. Thus, strict adherence to the 1/3
TDL guideline may not be appropriate for
all drugs. Use of 1/3 LD10 in mice as a
starting dose would have exceeded the
"commonly used human dose" in only 2
out of 19 trials (11%). Though these data
are not sufficient to imply that the mouse
offers a greater degree of predictability
than large animal species, this evaluation
is continuing.
Antitumour activity
Though screening for activity of new
drugs in various transplantable and carci-
nogen-induced animal tumours does take
place, there is no sure correlation between
activity in these systems and in human
tumours. It remains to be seen whether
activity in human tumours can be more
accurately predicted in human tumours
transplanted to nude mice. If this were
possible, it might improve the initial
screening for new drugs and even allow
screening for active drugs in individual
tumours.
Many animal models have high labelling
indices, though some recent systems, such
as the Lewis lung and B16 melanoma,
more closely mimic various human solid
tumours with low labelling indices. Most
importantly, we do not know whether
these systems are failing to detect active
drugs, only those drugs which show
activity in animal models being entered
into clinical trials.
The preclinical evaluation of new drugs
should also include the development of
methods of measuring tissue and blood
levels of the drug; these methods should
preferably be chemical rather than bio-
logical. As previously noted, the blood
level achieved may be much more accurate
in predicting toxicity and clinical activity
than a dose based on surface area or body
weight. The ability to measure drug levels
will also assist in obtaining as much
information as possible on absorption,
mechanisms of metabolism and routes of
excretion. Ideally, these pharmacological
data should be available from animal
studies prior to a drug being given in a
Phase I study. In addition, useful infor-
mation on drug interactions might be
obtained, though this has rarely been done
in the past.
Clinical studies
All clinical studies should consist of an
ethically designed experiment which sets
out to answer one or more specific
questions. For a clinicalstudytobe success-
ful, a written protocol is required, as there
are many different factors to be taken into
account. These include, at least, decisions
on the treatments to be studied, admis-
sion and exclusion criteria, randomization
and stratification, deviations from proto-
col, exclusions and withdrawals, and the
number of patients required to reach a
valid conclusion. All clinical trials in drug
development should ideally be prospective
A successful clinical trial is onethatreaches
the correct conclusion, not one that
produces a positive result.
Phase I Trials
A Phase I trial is essentially a clinical
pharmacological evaluation to establish
the maximum tolerated dose of a new
drug by a given schedule and route of
administration. It also identifies toxicity
patterns and whether toxicity is pre-
dictable, tolerable and reversible. A Phase
I trial is a studv oftherapeutic intent, but
lack of evidence of antitumour activity
should not be relied upon in the decision
on whether to proceed to a Phase II
study. Many of the patients who receive
drugs in Phase I studies are from a selected
population who are most unlikely to
respond to therapy. Investigators should
not be discouraged when a new drug shows
little or no activity in this setting: the
antitumour activity of new drugs can
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only be correctly ascertained in Phase II
and III studies.
When new anticancer agents are first
administered in patients, there is fre-
quently a lack of relevant data to suggest
safe methods of setting up the study.
Ideally, before beginning a Phase I
study the following information should
be available:
(1) A method (preferably chemical) of
measuring the compound in blood or
other body fluids.
(2) A knowledge ofblood levels achieved
by single, multiple and infusion techni-
ques of administration in several animal
species.
(3) A knowledge ofthe blood level ofthe
compound in relation to toxicity and
therapeutic action.
(4) The pharmacology ofthe drug should
be known in animal species, so that the
methods of administration and study of
human pharmacology are optimal.
All too frequently, drugs go into clinical
trials without this information available.
A question which has caused a great deal
of debate among medical oncologists is
whether a Phase I clinical trial of a new
drug should be deferred until the pharma-
cological methodology has beendeveloped.
This could delay clinical studies for a long
time. On the other hand, premature
clinical assessment may run the
risk of missing good drugs because they
have been given in an inappropriate
schedule, perhaps producing unnecessary
toxicity.
Dose escalation.-One of the most criti-
cal steps in setting up a Phase I study is
deciding on a starting dose and a method
of dose escalation which allows the
maximum tolerated dose (MTD) to be
reached safely and efficiently. One of the
more common methods used is the modi-
fied Fibonacci search scheme (Hansen
et al., 1971) which employs a fixed series of
dose escalations with decreasing incre-
ments. In the absence of toxicity the dose
escalations continue according to the
scheme. However, when mild but repro-
ducible toxicity is encountered, the escala-
tion is reduced to the 30-35% level until
the MTD is established. It has been
estimated that this method would re-
quire 5 (±3) dose escalations for most
drugs. Goldsmith etal. (1975) estimatedthe
number of escalations required to reach
the "commonly used clinical dose" for 30
compounds starting from 1/3 TDL for
dogs. Only 3 agents (10%) would have
required more than 8 steps ifthe modified
Fibonacci search were employed. There
are several other methods in use. Gottlieb
(1974) described a method starting at
1/3 TLD; he increased the dose by 50%
increments and decreased to 25% incre-
ments when toxicity was encountered.
Gold (1962) has proposed a geometric
progression of dose escalations, starting
at 1/100 the rodent LD50, but with its
progressively increasing doses per escala-
tion this method would probably result in
excessive toxicity for most compounds.
Currently, no statistical model for dose
escalation is inherently safe and efficient
for all drugs. Most investigators begin
with large increments (rarely more than
two-fold) when no toxicity is seen, and
decrease the escalations when minimal
toxicity is encountered. Currently, it is
the opinion ofmany workers that it is safe
to continue to double the dose as long as
no toxicity has been observed at the
previous level.
Dose escalation methods have not taken
into account blood levels ofthe compound
and correlated this with the toxicity
associated with similar levels in animal
models. Such techniques might allow
safer and more efficient dose escalation,
should a reproducible correlation exist
between toxicity and blood levels in
human and animal models.
In most trials, 3 patients are placed on
the initial dose and adequate time is
allowed for follow-up of delayed toxicity
before entering patients on the next dose.
As toxicity is encountered, more patients
are entered at each dose level until the
MTD is reached. Many investigators feel
that doses should not be escalated in
individual patients, as it becomes impos-
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sible to know whether a toxic effect is the
result of the cumulative dose or the
administered dose.
The goal ofa Phase I study is to find the
MTD for a particular drug schedule. In
practice the MTD achieved in any trial is a
function of the degree of prior therapy to
which the patients have been exposed and
their performance status. Patients of low
performance status who have received
extensive prior chemotherapy or radiation
therapy, will have less tolerance for further
chemotherapy. However, in the experience
of the authors there have been no cases
where the MTD derived in a Phase I study
has been increased by a subsequent Phase
II study. This may be related to the
expertise and support facilities available
to those who conduct Phase I studies, and
to the natural caution of investigators in
Phase II and III studies.
Phase I studies have essentially been
trials of toxicity, the end point being the
identification of the MTD. These studies
are also an ideal opportunity to gather
pharmacokinetic data. If these data are
collected, then selection of dose schedules
and methods ofreducing toxicity could be
the result of intelligent use of the data
rather than the use of routine screening
procedures.
Phase II Trials
Phase II trials are screening studies to
determine whether a new drug has anti-
tumour activity worthy of further clinical
evaluation. A Phase II trial is not planned
to define the ultimate role of the drug
under investigation. Many Phase II trials
use the maximum tolerated dose and
schedule derived from Phase I studies;
each Phase II study being a trial of the
particular dose and schedule used.
Animal studies have shown that the
therapeutic effects of many agents depend
on the dose schedule used. Unfortunately,
it has not been possible to use different
doses and schedules in many Phase II
studies. The danger in the use of set dose
schedules is that a drug may be judged
relatively inactive when used in a particu-
29
lar schedule and thus, not receive further
study. Such a drug might, however, have
been active when used in a different
schedule. In most present NCI trials, drugs
are given on an intermittent schedule
daily for 5 days or as a single dose, and
it is rare for different schedules to be
tested by a randomized comparison.
Decisions on drug dose and schedule are
thus made on the basis of non-random
comparison of their results achieved by
two routine scheduling methods. Indeed,
a particular schedule may be adopted
because it is that used in the first trial to
show antitumour activity of a drug.
Greater care in trial design, and more
attention to the pharmacokinetic data
gained in preclinical and Phase I studies,
might allow more rational choice of dose
and schedule regimes, rather than using
blind screening systems. Phase II studies
comparing various dose and schedule
regimes would undoubtedly be more com-
plex, requiring some of the mechanisms
previously employed in Phase III studies.
However, deciding on the dose and
schedule is clearly a very important step
in the development of a new drug, and
deserves to be treated in a less cavalier
fashion than at present.
On the completion ofa Phase II study a
reasonable estimate of the efficacy of the
drug used in a particular dose schedule
should be available. In addition, further
more definitive information on drug toxici-
ties should be available. The decision to
continue drug development in a Phase III
study will be made on this data, which can
be treated as a risk-benefit ratio.
Tumour-orientated trials.-When effi-
ciency is the criterion for the advisability
forfurther trials, Gehan and Schneiderman
(1973) have pointed out that the decision
to be reached is whether or not an agent
can be effective in x% ofpatients or more.
The answer can usually be reached in a
relatively small number of patients. The
value of x% will vary according to the
efficacy ofdrugs that are already available
for the treatment of a particular tumour,
and in non-randomized studies the appro-
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priate value ofx is usually subject to some
uncertainty.
The original type of Phase II study,
using a large number of patients with
tumours of many differing types, is
probably no longer applicable. Using this
type of drug-orientated study design,
small numbers of patients with many
different tumours are treated and it is not
possible to estimate the usefulness of a
drug schedule in any one tumour; only an
estimate of efficacy in broad tumour types
is gained. There are many factors, such as
performance status, prior treatment, site
ofdisease, type ofhistology etc., which can
effect the outcome of treatment, and data
from a few patients of each tumour type
cannot be relied upon. The greatest risk
in such a Phase II study is the erroneous
conclusion that a drug has little activity
and does not require further study. Phase
II studies should, therefore, preferably
be tumour-orientated; a 20-30% response
rate in renal cell carcinoma is very differ-
ent from a similar response rate in
Hodgkin's disease.
Tumour response.-The current end
point used in Phase II studies is a measur-
able reproducible decrease in the size of a
lesion, lasting a specified time. Ideally, all
patients entering such a study should,
therefore, have easily measurable disease.
Though this is frequently the case, there
are certain tumours, such as ovarian can-
TABLE I. Commonly Used Criteria for
Objective Response and Disease Pro-
gression in Solid Turnours
Complete response Complete (lisappearance of all
demonstrable disease.
Parti(al responise > 50% reduction in the sum of
the pro(lucts of the longest
perpendicular diameters of
discrete measurable (lisease,
with no (lemonstrable
disease progression else-
where.
No response <50% re(luction or increase of
measurable (lisease as
(lefined above.
Progression > 50% increase in the stum of
the products of the largest
perpen(licular diameter of
any meastirable lesioni.
cer, where it can be difficult to measure
responses accurately and the parameters
upon which response is judged must,
therefore, be clearly defined.
The most common criteria for tumour
response when there is easily measurable
disease are shown in Table I. All responses
should be ofat least one month's duration.
In addition to the usual parameters of a
50% change in the products of the longest
perpendicular diameters of a measurable
lesion (shown to be reasonably accurate by
Moertel et al. (1974)) we hope that the
introduction of tumour markers will allow
more accurate assessment of tumour
response to treatment.
Survival may also be used as an end
point in Phase II studies when life
expectancy is very short. Survival, how-
ever, is a much more stringent criterion
than tumour response, and a majority of
patients with increased survival will be
needed to improve a median survival, so
that only particularly active drugs will be
identified.
Study design.- The role of known prog-
nostic factors in a randomized study
design has already been discussed. A
relatively large number of patients must
be entered into a study, so that random
(and, we hope, equal) distribution of
known and unknown prognostic factors
occurs. It is possible by "stratification"
to ensure that the known important
prognostic factors are evenly distributed
within "stratum" in a trial. Simple
randomization would not necessarily en-
sure equal distribution of known prognos-
tic factors, particularly in relatively small
trials such as most Phase II studies, though
it may be possible to allow for this when
the data are analysed (Peto et al., 1976,
1977).
In a non-randomized Phase II study,
all patients are given a single treatment.
The study should be designed in such a
way that known prognostic factors are
recorded for each new patient admitted.
Thus, patients of poor performance status
after multiple chemotherapy and radia-
tion therapy can be analysed separately
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from newly diagnosed patients of good
performance status. However, there may
still remain some uncertainty about the
interpretation of such studies, for the
"expected" outcome in a particular group
ofpatients can never be predicted exactly.
The study design, and patients accrued
to a trial, depends very much on the
tumour being studied. There are basically
4 groups of patients with cancer available
for study, each defined by its responsive-
ness to other chemotherapies (Table II).
TABLE II. Suitability of Tumour Types
for Phase II Trials
(1) Tumouirs in which Phase IT studies ofinewT (frtogs
are feasible in newu patieunts:
Bronchogenic carcinoma
Pancreatic carcirnoma Peseiit (lrugs Malignant melanoma iniactive Bladder carcinoma I
Oesophageal carcinoma J
(2) Tumours in which an argument can be ma(le for
"standlar(l" treatmeint before Phase II studies:
Large bowel carcinoma
Head andl neck cancer Presenit (ruggs
Brain tumoturs of modlerate
Stomach cancers activity
Uterine cervix cancer J
(3) Ttimours in which "standlardl" treatment is
usually givein before Phase 11 sttu(lies:
Acute leukaemias
Malignant lymphomas
Chronic leuikaemias
Multiple myeloma Present (Irugs
Breast cancer highly active
Ovarian cancer
Soft-tissue an(l bone sarcomas
Testicular carcinoma
(4) Tumoutrs where preseiit (frtogs shouildI be evaltna-
ted before inivestigational dlruigs:
Prostate a(leinocarcinioma
Renal carcinoma
Endometrial caircinoma
At present, there are still tumours for
which there is little or no active chemo-
therapy; a new drug can, therefore, be
used ethically as initial therapy in Phase
II studies in these patients. A second
group of patients exists for whom chemo-
therapy of low or moderate activity is
available. If no substantial benefit can be
demonstrated for these patients with
standard chemotherapy, then a case for
initially treating these patients with
investigational drugs can be made, as new
drugs would not receive adequate evalua-
tion ifused only in patients with advanced
disease. A randomized study using the
standard agent as a control might be an
appropriate means of detecting drugs of
equal or greater effectiveness.
Tumours for which effective chemo-
therapy is available pose a different
problem. Patients must receive standard
chemotherapy before investigational drugs
can be ethically used in a Phase II study.
This may entail several treatment regimes
in some tumours such as Hodgkin's
disease, so that only "end-stage" patients
are available for Phase II study. However,
if efficient treatment is already available,
only drugs which are especially active
will need to be detected; which may be
possible. Detecting new drugs oranalogues
of present drugs which have moderate
activity but low toxicity, and thus
suitable for combination, will be very
difficult. The development of analogues
of existing drugs will in particular pose
major problems in study design, as it will
often be unethical to administer them
before their parent compound. Assess-
ment of toxicity of potentially less toxic
analogues will, of course, be possible in
patients with tumours unresponsive to
present therapy.
The fourth small group is composed of
patients in whose tumours few or no
drugs have been adequately evaluated.
Clinical trials in these patients should, as a
first priority, test drugs known to be
active in other tumours, rather than
investigational drugs.
Two Phase II study designs that use
standard treatment as a control are shown
in Fig. 3 (Plans A, B and C). Stratification
of patients is performed in both studies.
Randomization to standard therapy ac-
complishes 2 purposes. Firstly, it allows
testing of a new regime in previously
untreated patients and relatively respon-
sive patients. Secondly, at least half the
patients will receive standard treatment,
though it should be remembered that
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Plan A
Plan B
Plan C
Key
-Randomisation
Stratification -- Randomisation
U
Stratification *Randomisation<
ut
U U
Stratification o- Randomisation<
S = Standard agent
U = Untested agent
U'= Second untested agent
FIC.. 3. Designis for randomized Phase 11 studies.
randomization does not have to be in a
ratio of 1: 1 (e.y. the ratio of new treatment
to standard treatment might be 2: 1
(Peto et al., 1976, 1977) allowing more
patients to receive the new treatment).
If there is a crossover, as in Plan A, all
patients will receive standard therapy at
some time in the course of treatment.
A crossover may be designed to occur at
a fixed time or when disease progression
occurs. When the latter is the case, the
effectiveness of agents as secondary
therapy can be evaluated and some infor-
mation on cross resistance ofthe 2 regimes
obtained. In addition, time to progressive
disease can be used as another parameter
ofthe first treatment regime. Non-random-
ized Phase II trials, as previously dis-
cussed, may be used in tumours where no
standard treatment exists despite adequate
evaluation of existing drugs (although
even then it may be wise to randomize
between the new drug and an untreated
control group). Tumours where drugs have
not been adequately tested should be the
subject of trials of drugs which are
active in other tumours. These studies
could be performed efficiently as a random-
ized study of 2 different drugs with a
crossover (Fig. 3, Plan C). They could also
be studied in a consecutive non-random-
ized manner in relatively good-risk
patients, again with the extra uncertain-
ties in non-randomized treatment com-
parisons.
The 4 groups of tumours, as defined by
responsiveness to present drugs, are fluid
and, as chemotherapy improves, most
patients will fall into the group where we
already have highly effective treatment,
and where Phase 11 studies only become
ethical when the patient is least likely to
respond to further drug therapy. We are,
therefore, going to require new and more
sensitive methods of detecting the thera-
peutic potential of new drugs. Whether
in vitro tumour-cell-culture assays, or
assays using tumours transplanted into
nude mice, will be of use remains un-
answered. However, it is clear that only
drugs which are highly active will be
detected by present methods in patients
with advanced disease which is resistant
to current therapy. However, it must be
remembered that only such drugs will be
required, if effective treatment is already
available. The detection of equally active
but less toxic drugs will, however, remain
a problem.
Phase III Trials
Phase III trials are an attempt to
determine the role of a new drug in the
practice of oncology. These studies are,
therefore, complex and require good data
collection and quality control.
Classically, a Phase III study tests a
new drug against a standard agent, but
the present emphasis on disease-orientated
trials may mean that a new drug often
enters Phase III in combination with other
standard agents.
Stratification. Simple randomization
does not guarantee an equal balance of all
important known prognostic variables
between treatment groups. Though strati-
fication, prior to randomization, has
frequently been employed to ensure a
balance of prognostic factors between
groups, many statisticians (Peto et al.,
1976, 1977) now agree that the benefits of
this method are not great, as long as
appropriate modern methods of statistical
analysis are used.
The main advantages of pre-randomiza-
tion stratification are apparent in very
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small trials. Stratification at entry will
ensure a reasonable balance of patients
receiving each treatment and will avoid a
situation in which almost all the patients
in one retrospective stratum get the same
treatment. Such a situation is likely to
arise only in a very small trial.
Control groups.-The control groups in
clinical trials have been of 2 basic types:
(1) patients treated concurrently and
randomly assigned to this group, and (2)
those selected from past records and
termed "historical controls".
It has been suggested (Gehan and
Schneiderman, 1973; Gehan and Freireich,
1974; Farber, 1966) that careful selection
of controls from the literature, matched
controls from a particular group or
institution, or controls from sequential
studies, may provide an adequate group
for comparison with a new therapy. This
has not proved to be so. Selection of
comparable controls requires an attempt
at balancing known prognostic factors
and, as Schneiderman pointed out, the
use of historical controls almost assumes
that you know all you will need to know
about what determines responses in
patients. This is hardly ever true; new
prognostic variables are constantly being
uncovered or rediscovered. The introduc-
tion oftumour markers andimmunological
tests will continue to provide further
information on prognostic variables. Not
only are prognostic variables improperly
understood; many Phase II studies are
performed without attempts to "match"
the historical control. Use of historical
controls can also be questioned because
apparent improvement observed with a
new therapy may be due to poorly under-
stood factors, such as:
(1)Patientspresenting earlierfordiagno-
sis and treatment at University centres,
and when treatment is thought more
likely to be successful.
(2) Improved ancillary care, which may
allow a better response rate.
(3) Improvement of physicians' exper-
tise with time and greater enthusiasm
about the current study.
Traditional tests of statistical signifi-
cance are frequently applied to trials
with historical controls; this is statisti-
cally incorrect, especially so in those
studies where no attempt has been made
to balance the prognostic factors.
Statistical analysis.-The analysis of
randomized controlled Phase III trials
requires the application of statistical
techniques. Clinicians reading reports of
clinical trials must be able to distinguish
the results which could be artifacts of
chance from those which could not. Even
in a stratified and randomized study
unknown sources of error may influence
the result. If a group of patients receiv-
ing one treatment does better than another
group treated with a second treatment,
there are 2 possible explanations: either
the first group received superior treat-
ment or there was a disproportionate
number of patients who would have done
well anyway in this group. The rationale
for study design, objective assessment and
follow-up is to ensure that, ifa substantial
difference is demonstrated between the
2 treatments, a P value can be calculated
to help discriminate between the alterna-
tives.
Study design
Once the type of trial to be undertaken
has been decided, a protocol must be
written. A protocol should ideally outline
the rationale for the study and then give
strict guidelines for admission criteria and
exclusion. Most protocols involve selec-
tion of specific patients by various
factors (i.e. age, stage, performancestatus).
The outcome of the study is, therefore,
related to these particular patients treated
in a specific manner. Every study involves
the following sequential flow of patient
numbers:
(1) Number evaluated for entrance into
the study, i.e. all patients with the disease
type and stage to be studied.
(2) Number eligible for entrance into the
study, i.e. those patients who fit the speci-
fic criteria for admission into the study
within the disease type and stage.
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(3) Number entered.
(4) Number evaluable, i.e. those patients
who have received the number of treat-
ment courses specified by the protocol.
Later exclusion of the non-evaluable
patients is often an error.
The denominator used in determining
response frequently becomes progress-
ively smaller, from those considered for
entrance to those "adequately treated".
There must therefore be careful presenta-
tion and analysis of all patients con-
sidered non-evaluable or inadequately
treated. Specific instructions regarding
patients whose treatment deviates from
the protocol or who withdraw from the
trial should be written into the protocol;
it is not adequate to decide at the end ofa
trial how these patients should be ana-
lysed. Exclusions do not bias a study, as
these patients are not entered into the
study, but withdrawals, e.g. of non-
evaluable patients can bias a study. For
example, only those patients who are
well enough might contemplate leaving a
study, and would thus have a negative
effect on the results. Attempts should be
made to follow-up all patients even if
they withdraw from the study.
Care should also be exercised when there
is doubt about the diagnosis. This may be
solved by not randomizing until the diag-
nosis is unequivocal, or by randomizing all
patients in whom the diagnosis is in
doubt and by including all patients in the
analysis, regardless oftheir final diagnosis.
Alternatively, all patients could be ran-
domized, and those patients in whom the
diagnosis is changed could then be
excluded from the analysis. This might
be more appropriate when blind review is
undertaken by a critical review board, and
may be advantageous if review is under-
taken at the end of the trial, as there will
be greater uniformity in interpreting
histopathology. Treatment deviations
from the protocol should not be excluded
from analysis, as this may seriously bias
the result. If these patients are excluded,
this should be stated and included in the
analysis of the study.
The exclusion ofpre-treatment or early-
treatment deaths in a treatment group
may also seriously bias the trial, and
should be avoided, especially when there
is an untreated control group. If early
deaths are excluded from analysis, severe
drug-related toxicity may be ignored and
an unwarranted favourable result re-
ported. A clinical trial is a study of a
group of patients as defined by the entry
criteria. If this group includes some
early deaths, then they should be included
in analysis; patients unlikely to die early
could, if desired, have been selected by
different entry criteria.
It is very important to have an estimate
of the number of patients required to
answer the question posed by the study.
This is more related to the number of
patients reaching the end point of the
study, i.e. relapse or death, than to the
total number entering to the study. Peto
et cl. (1976, 1977) conclude that clinical
trials can easily monitor end-point ratios
between treatments which are 1: 3 or
better, but that detection of anything less
extreme than 2:3 is very difficult. Thus,
if the end-point ratio (i.e. death ratio) is
1: 3, a trial in which 40 patients die has an
80% chance of reaching a statistically
significant result. However, if the end-
point ratio is 2:3, a trial in which 100
patients die would only have an even
chance of reaching a statistically signifi-
cant result, and a trial including 200
deaths may be required. (The number of
patients entering a trial is, therefore,
crucial; estimates of this figure require a
knowledge of the expected difference
between the 2 groups or at least the
smallest difference which can usefully be
detected).
Sequential analysis methods, which
compute a P-value on the assumption
that frequent examination ofthe data will
occur, may be preferred. However, this
type of analysis is complex and time con-
suming. Most statistical methods applied
to clinical trials are only valid if the
decision to analyse is independent of the
current results. This is, of course, un-
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likely to lhappen in most trials. If frequent
"previews" of the data are undertaken,
the decision to stop and analyse the
trial may be influenced by the opinion
that it is likely to show a significant
difference between the treatment groups.
Clinicians reading the results of clinical
trials should be extremely critical of the
methods of trial design and analysis.
Adequate assessment of a trial can only be
made if the authors provide all the data
and an outline of the protocol. The
achievement of a significant P-value is not
the aim of a trial, and excessive reliance
on P will be misleading in some cases.
A P-value is only of importance if it can
be demonstrated that the trial has been
run in such a way that statistical analysis
is valid, which is usually so in a ran-
domized prospective study undertaken
with scrupulous care. The achievement of
particular P-value in a trial will, of course,
be interpreted in the light of a clinician's
experiences and perhaps prejudices (Peto
and Doll, 1977).
For further details on the analysis of
clinical trials, Peto et al. (1976, 1977) pro-
vide guidance and many examples in the
second part of their paper.
Combined modality trials
It is only very recently that combined
modality approaches to cancer have
become more commonly used. Paediatric
oncology has shown that such an approach
can be successful in Wilms' Tumour
(Sutow et al., 1970; Sullivan and Sutow,
1969) embryonal rhabdomyosarcoma
(Pratt et al., 1972; Pinkel and Pratt, 1]973)
and Ewing's sarcoma. Adult oncologists
are now exploring combined modality
approaches in adult cancer with some
early successes in breast cancer (Fisher
et al., 1975, Bonadonna et al., 1976).
Examination of the natural history and
modes of spread of various tumours has
shown that local modalities of therapy
frequently fail to produce cures, as the
disease is already microscopically dis-
seminated at presentation. Present clinical
tools are only capable of demonstrating
tumour when high cell burdens are
present (.109 cells). Systemic therapy is
therefore required to eradicate this unseen
mass of malignant cells.
Study of the natural history of various
diseases has led to the identification of
various groups in whom microscopic
dissemination and tumour progression is
likely. Combined modality trials have
been concentrated in these high-risk
groups, which include:
(1) breast cancer with positive axillary
nodes,
(2) large bowel cancer with disease pene-
trating the bowel and/or involving the
regional lymph nodes and
(3) patients who have had attempted
curative resection of gastric, pancreatic
or lung cancer.
If disseminated disease does exist,
systemic therapy is required to control
disease elsewhere in the body. Thera-
peutic modalities with this potential
include chemotherapy, immunotherapy,
whole-body irradiation and endocrine
manipulation. Chemotherapy is undoubt-
edly the most active of these modalities
available, with a known ability to pro-
duce remissions and "cures" in some
cancers when either single drugs or
combinations are used.
Chemotherapy has been shown experi-
mentally to be most effective when the
tumour burden is low and kills by first-
order kinetics (fixed percentage kill) so
that, when the tumour burden is low,
total cell kill may occur with a reason-
able number of repetitive doses before
resistance can develop.
The degree of drug activity which is
required in advanced disease for therapy
to be successful in an adjuvant study is
not known. Currently it is assumed that
drugs or combinations of drugs which are
capable of objective responses (500
reduction in tumour mass) in advanced
disease will be capable of total cell kill
when used for residual disease after local
modality therapy. The level of activity
(complete or partial remission rate) re-
quired is not known. It is encouraging
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that L-PAM (Fisher et al., 1975) with a
20% objective remission rate has achieved
some preliminary success in Stage II
breast cancer when used as an adjuvant.
However, 5-fluorouracil (Carter, 1976) has
apparently not been of use as an adjuvant
in large bowel cancer, despite a similar
objective response rate. Explanations for
such differences include variation in resid-
ual tumour burden, cell kinetics and drug
availability at a tumour cell site.
Trials designed to examine the role of
combined modality and adjuvant treat-
ment should always be randomized pro-
spective controlled studies. The mecha-
nisms used in Phase III studies will need
to be applied. Large numbers of patients
will be required to demonstrate relatively
small but important (10%) gains in survi-
val. Long-term follow-up will be required
to accurately assess any improvement in
survival rates (early reporting ofdata may
give a spurious impression as delay in
recurrent disease and not "cure" may
result). It is possible that adjuvant
therapy may compromise the ability to
palliate patients after tumour recurrence,
so that there is little overall impact on
survival.
Long-term follow-up is also required to
ensure that chronic and late-onset toxicity
are adequately assessed. The incidence of
second malignancies following combined
radiation and chemotherapy is unknown,
though it is clear that the leukaemia
incidence is increased (Williams et al.,
1977).
Combined modality trials not only need
stringent design in order to produce valid
results; they will require that we set up
accurate methods oflong-term data collec-
tion and close patient follow-up. The long-
term collection of data is aided in the
United Kingdom by the Office of Popula-
tion Census and Surveys. By prior arrange-
ment they will, ifgiven the full names and
exact dates of birth of all trial patients,
notify the trial organizer whenever any
deaths occur, giving the date and certified
cause ofdeath and name ofphysician who
certified the death. Adequate follow-up of
survival is thus made much easier in
Britain than many other countries.
The introduction ofcomputers has made
feasible long-term collection of data, but
its accurate recording is still in the hands
of clinicians. Ideally, clinical trials should
not run more than 2 years, as enthusiasm
for a project wanes rapidly after this
time. Ifwe are to envisage prolonged data
collection for 10 years or more in some
adjuvant trials, physician apathy may be
a major problem, particularly in multi-
centre trials. Trials run by involved
investigators in a single large institution
may have an advantage in this respect,
although in general, single institutions will
not be able to accrue enough patients in a
short time to undertake such studies.
REFERENCES
BONADONNA, G., BRUSCAMOTINO, C., BALAGUSSA, P.,
Rossi, A., BRUGNATELLI, L., BRAMBILLA, C.,
DELENA, M., TANCINI, G., BAJETTA, E., Muscu-
MECI, R. & VERONESI, U. (1976) Combination
Chemotherapy as Adjuvant Treatment in Oper-
able Breast Cancer. New Engl. J. Med., 294, 405.
CARTER, S. K. (1973) Some Thoughts on Experi-
mental Models and their Clinical Correlations.
Eur. J. Cancer, 9, 833.
CARTER, S. K. (1976) Large Bowel Cancer: the
Current Status of Treatment. J. natn. Cancer
Inst., 56, 3.
FARBER, S. (1966) Chemotherapy in the Treatment
of Leukaemia and Wilm's Tumour. J. Am. med.
Ass., 198, 826.
FISHER, B., CARBONE, P., EcoNoMou, S., FRELICK,
R., GLASS, A., LERNER, H., REDMOND, C.,
ZELEN, M., BAND, P., KATRYCH, D., WOLMARK,
H. & FISHER, E. (1975) L-phenylalanine Mustard
(L-PAM) in the Management of Primary Breast
Cancer: a Report of Early Findings. New Engl. J.
Med., 292, 117.
FREIREICH, E. J., GEHAN, E. A., RALL, D. A.,
SCHMIDT, L. H. & SKIPPER, H. H. (1976) Quantita-
tive Comparison ofToxicity ofAnti-cancer Agents
in Mouse, Rat, Hamster, Dog, Monkey and Man.
Cancer Chemother. Rep., 50, 219.
GEHAN, E. A. & FREIREICH, E. J. (1974) Non-
randomized Controls in Cancer Clinical Trials. New
Engl. J. Med., 240, 198.
GEHAN, E. A. & SCHNEIDERMAN, M. D. (1973)
Experimental Design of Clinical Trials. In Cancer
Medicine. Eds J. F. Holland and E. Frei. Phila-
delphia: Lea & Febiger. p. 499.
GOLD, L. (1962) Co-ordinated Phase I Studies for
Co-operative Chemotherapy Groups. Cancer
Chemother. Rep., 16, 99.
GOLDSMITH, M. A., SLAVIK, M. & CARTER, S. K.
(1975) Quantitative Prediction of Drug Toxicity
in Humans from Toxicology in Small and Large
Animals. Cancer Res., 35, 1354.
GOTTLIEB, J. A. (1974) Phase I and II ClinicalCANCER CHEMOTHERAPY TRIALS 447
Trials: a Critical Reappraisal. In Pharmacologic
basis of cancer chemotherapy. Baltimore: Williams
and Wilkinson.
HANSEN, H., SELAWRY, 0. S., MUGGIA, F. M. &
WALKER, M. D. (1971) Clinical Studies with 1-
(2-chloroethyl)-3-cyclohexyl-l -nitrosourea (NSC
79037). Cancer Res., 31, 223.
HOMAN, E. R. (1972) Quantitative Relationships
between Toxic Doses of Anti-tumour Chemo-
therapeutic Agents in Animals and Man. Cancer
Chemother. Rep., 3, 13.
MOERTEL, C. G., SCHUTT, A. J., HAHAN, R. G. &
REITEMEIER, R. S. (1974) Effects of Patients
Selection on Results of Phase II Chemotherapy
Trials in Gastro-intestinal Cancer. Cancer Chemo-
ther. Rep., 59, 257.
OWENS, A. H. (1962) Predicting Anti-cancer Drug
Effects in Man from Laboratory Studies. J. chron.
Dis., 15, 223.
PETO, R. & DOLL, R. (1977) When is Significant not
Significant? Br. med. J., ii, 259.
PETO, R., PIKE, M. C., ARMITAGE, P., BRESLOW,
N. E., Cox, D. R., HOWARD, S. V., MANTEL, N.,
MCPHERSON, K., PETO, J. & SMITH, P. G. (Part I,
1976; Part II, 1977) Design and Analysis of
Randomized Clinical Trials Requiring Prolonged
Observation of Each Patient. Br. J. Cancer, 34,
585 and 35, 1.
PINKEL, D. (1958) The use of Body Surface Area
as a Criterion of Drug Dosage in Cancer Chemo-
therapy. Cancer Res., 18, 853.
PINKEL, D. & PRATT, C. (1973) Emnbryonal Rhabdo-
myosarcoma. In Cancer Medicine. Ed. J. F.
Holland and E. Frei. Philadelphia: Lea and
Febiger. p. 1900.
PRATT, C. B., HUSTEN, H. O., FLEMING, I. P. &
PINKEL, D. (1972) Co-ordinated Treatment of
Childhood Rhabdomyosarcoma with Surgery,
Radiotherapy and Combination Chemotherapy.
Cancer Res., 32, 606.
SCHEIN, P. S., DAVIES, R. D. & COONEY, D. A. (1973)
Qualitative Aspects of Drug Toxicity in Predic-
tion from Laboratory Animals to Man. In
Pharmacology and the Future of Man, Proc. 5th
Int. Cong. Pharmacol. San Francisco., 3, 304.
SULLIVAN, M. P. & SUTOW, W. W. (1969) Successful
Therapy for Wilms' Tumour. Tex. Med., 65, 46.
SUTOW, W. W., GEHAN, E. A., HEYN, R. M., KUNG,
F. H., MILLER, R. W., MURPHY, M. L. & TRAGGIS,
D. G. (1970) Comparison of Survival Curves, 1956
versus 1962, in Children with Wilms' Tumour and
Neuroblastoma. Paediatrics, 45, 800.
WILLIAMS, C. J., COLEMAN, C. N., GLATSEIN, E. J.,
ROSENBERG, S. A. & KAPLAN, H. S. (1977) Hemat-
tologic Malignancies in Remission of Hodgkin's
Disease. Proc. Am. Ass. Cancer Res., 18, 288.